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Purpose/Objective: As stereotactic radiotherapy becomes 
part of the clinical routine in more and more centres, the 
need for audit procedures and tools increases. Any audit of 
stereotactic radiotherapy should address position and 
delivered dose with equal importance. At the same time, 
measurement of dose in small stereotactic fields necessitates 
fine positioning of the probe. Preferably an audit should be 
uncomplicated and fast to perform. Considering those 
requirements, a new audit tool is presented, which allows 
audits to be performed efficiently either by an onsite team or 
as a postal audit.  
Materials and Methods: A Stereotactic Cube phantom has 
been designed to perform Winston Lutz type position 
verification measurements and dose measurements in one 
setup. The phantom comprises a plastic cube with a high 
density ball in its centre, low density spheres in the 
periphery, strategically placed gold markers near the 
posterior and right surfaces and slit-like openings to insert 
film or other detectors for dose measurement. For the end to 
end procedure the phantom is first scanned. A treatment 
plan is created with dose delivered to one or both of the 
measurement locations using small fields. The fields do not 
traverse any of the high or low density material. The 
phantom is setup at the delivery system using 3D imaging. 
Film has been attached to the phantom at two locations and 
an orthogonal pair of static beams is delivered for position 
verification. The exposed films show shadows of the centre 
ball and the other high density markers. Based on the 
position of the centre marker on the images relative to the 
field dimension and to the other markers, the alignment of 
the phantom in all six dimensions can be verified using image 
analysis of the scanned films. Alternatively these images can 
be collected with an MV EPID. Dose measurements are 
performed with either an ionization chamber or solid state 
detector, which would have been in place during alignment, 
or with film, which is inserted into the phantom just prior to 
exposure. 
 
Figure: Axial cut view: high density ball at centre (1), low 
density objects for kV CBCT alignment in periphery (2-4), 
simulated beam (5), gold markers (6, 7) to show rotational 
alignment in MV imaging on film (8, 9) or EPID (not shown) . 
Insert for dose measurement (10 – film option shown). 
 
Results: Measurements with a prototype of the cube showed 
excellent suitability for cone beam computed tomography 
(CBCT) 3D alignment. While high density markers naturally 
degrade CBCT images through artefacts, the position and 
good visibility of the low density markers allowed for robust 
alignment of the cube. MV imaging with film and EPID 
allowed for clear identification of all markers. Dose 
measurements were performed with film, while the insert for 
a small ion chamber is still under construction. 
Conclusions: A phantom and methods for an uncomplicated 
stereotactic audit considering position and dose have been 
developed and tested. 
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Purpose/Objective: A treatment planning system (TPS) 
should be verified in a real 3D situation with rigorous 
procedures, both for static and rotational modulated 
techniques. The American Association of Physicists in 
Medicine Task Group 119 (TG119) proposed a water 
equivalent square slab phantom (30x30x15 cm3) with four 
IMRT tests: Mock Prostate, Head-and-Neck, C-shaped target, 
and Multi Target. Each test was developed to assess the 
overall accuracy of planning and delivery of IMRT treatments. 
TG119 defines also beam arrangements, goals, and methods 
to analyze dosimetric results. The AAPM phantom is cheap 
and easily reproducible in every department, but it allows 
only single point or single planar measurements. In this work 
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we propose to adapt the TG 119 to VMAT treatments using a 
different 3D cylindrical dosimetric phantom. 
Materials and Methods: TG119 structures were superimposed 
on the CT images of a cylindrical PMMA phantom surrounding 
two orthogonal matrices with 1069 total diodes (Delta4 - 
Scandidos, SWE). TG119 tests were thus calculated and 
optimized using Monaco 3.3 (Elekta, SWE) and, recently, 
recalculated with the new version 5, for 6 and 10 MV photon 
beams, for VMAT techniques, following all plan goals 
proposed by TG119. Delta4 phantom was used in order to 
carry out a comparison between measured and planned 3D 
absolute dose distributions. A 3%, 3mm gamma test (global 
and local) with a 10% threshold (defined by the isodose line 
representing 10% of maximum dose) was used for plans 
analysis and Confidence Limits (CL = |100 – mean| +1.96 * SD) 
were also generated. 
Results/ Goals proposed in TG119 were mostly satisfied for 
each plan and technique except for the Multi Target, where 
the dose at 99% of the volume (D99 goal) to the central 
volume was not achieved. The range of global gamma passing 
points was 98.4% – 99.7% of total compared points, with a 
mean percentage value of 99.1 ± 0.5% for all photon energies 
and all plans thus generating a confidence limit of 2.3% and 
1.5% for 6 and 10MV photons beam respectively. The range of 
local gamma passing points was 96.2% – 98.9%, with a mean 
percentage value of 97.7 ± 1.1%, now generating a 
confidence limit of 5.4% and 2.6% for 6 and 10MV 
respectively. 
Conclusions: TG119 structures and plans were found to be 
adaptable to VMAT treatments and Delta4 phantom, enabling 
a more exhaustive evaluation procedure, although this 
solution is also more expensive than the TG119 one. The use 
of a local gamma stresses all outcomes thus highlighting any 
local critical area. CLs allow to generate 'in house' reference 
values to evaluate the overall result of the entire dosimetric 
process involved in volumetric treatments. Even in the worst 
case CLs are well lower than the reference one proposed in 
TG119 (12.4%). Concluding, even if not designed for IMRT, 
our results showed that TG119 can be a practical 
commissioning procedure for VMAT therapy too. 
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Purpose/Objective: An EPID-based in-vivo dosimetry method 
for 3D-conformal radiotherapy (DISO) and widely used in 
several Italian Centers has now been expanded to VMAT 
technique. In this study we prospectively evaluated this 
transit dosimetry algorithm for complex VMAT treatments 
and analyzed the issues and challenges for a large-scale 
adoption in clinical routine. 
Materials and Methods/ 20 consecutive patients with head-
and-neck tumors and treated with SIB-VMAT using Elekta 
Precise linacs were enrolled. All plans were generated with 
Oncentra Masterplan TPS and optimized in dual-arc modality. 
Three targets were simultaneously irradiated over 30 daily 
fractions. Doses of 70.5, 60.0 Gy and 55.5 Gy were prescribed 
to primary tumor, high-risk lymph nodal region and low-risk 
nodal region, respectively. All patients passed pre-treatment 
3%/3mm γ-analysis verification with γ pass-rate of more than 
95%. In-vivo tests were evaluate by means of (i) ratio R 
between daily in-vivo isocenter dose and planned dose and 
(ii) γ-analysis between EPID integral portal images in terms of 
percentage of points with γ-value smaller than one (γ%) and 
mean γ-values (γmean), using a global 3%-3mm criteria. Alert 
criteria of ±5% for R ratio, γ%>90% and γmean<0.67 were 
chosen, the last two in order to accept only 10% of the values 
to exceed 3%/3mm and an average discrepancy of the order 
of 2%/2mm, respectively. 
Results: A total of 368 transit EPID images, two images for 
each VMAT plan, were acquired during the treatment 
fractions of 20 patients. 28 images (7.6%) were removed from 
analysis for image deterioration and/or electronic acquisition 
failures. The overall mean R ratio was equal to 1.000 ± 0.026 
(1SD), with 92.1% of tests within ±5%. The 2D portal images 
γ-analysis show an overall γmean of 0.44±0.18 with 90.0% of 
tests within alert criteria, and a mean γ% equal to 91.9±5.7% 
with 75.8% of tests within alert criteria. 54 (16%) 2D portal γ-
tests showing lower values of γ pass-rate were associated 
with dose discrepancies. In particular, clinical relevant 
discrepancies were observed in four patients: a set-up error 
was detected at the beginning of treatment for one patient 
and three patients showed major anatomical variations 
(weight loss/tumor shrinkage) in the second half of 
treatment. The results are supplied in quasi real-time, with 
in-vivo tests performed and displayed after only 1 minute 
from the end of arc delivery. 
Conclusions: Our EPID-based in-vivo dosimetry algorithm 
provided a fast and accurate procedure for VMAT delivery 
verification in clinical routine. An efficient procedure allow 
to obtain the results within 1 minute after each arc delivery. 
This procedure was able to detect when delivery was 
inconsistent with the original plans, allowing physics and 
medical staff to promptly act in case of major deviations 
between measured and planned dose.  
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